[
  {
    "question": "case of RRMS with hx of type1 DM, depression, what is the best treatment for her:",
    "option_a": "Fingolimod",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune demyelinating disorder of the central nervous system. Disease-modifying therapies (DMTs) are used to reduce relapse frequency and slow disease progression. Selection of DMTs is influenced not only by efficacy but also by the patient\u2019s comorbidities; in this case, type 1 diabetes mellitus and depression are important considerations. MS is characterized by an immune-mediated attack on myelin and axons in the CNS. DMTs work by modifying or suppressing this aberrant immune response. For instance, glatiramer acetate is believed to act as a decoy antigen, inducing regulatory T cells that help suppress inflammatory processes, while interferon-beta has multiple immunomodulatory effects but may worsen depressive symptoms. In patients with RRMS who also suffer from depression, interferon-beta may exacerbate mood symptoms. Likewise, coexisting autoimmune conditions (like type 1 DM) make it imperative to choose a therapy with a favorable overall safety profile. Glatiramer acetate is well tolerated and is often preferred in individuals with depression, as it is not associated with flu\u2010like symptoms or mood deterioration. The diagnosis of MS is established using the McDonald criteria, which require evidence of lesions in time and space. MRI evaluation, cerebrospinal fluid analysis, and clinical history are essential to confirming the diagnosis and monitoring disease progression. First-line DMTs for RRMS include interferon-beta and glatiramer acetate. In patients with depression, glatiramer acetate is generally preferred over interferon-beta because it has a minimal effect on mood. During pregnancy and lactation, glatiramer acetate is considered relatively safe compared to many other DMTs (often used when the risk-benefit ratio justifies treatment), although treatment decisions should involve a discussion between the patient and her healthcare provider. If a woman is planning pregnancy, careful planning and possibly temporary discontinuation or switching to a pregnancy-compatible agent might be considered. Option A (Fingolimod) is an oral agent effective in RRMS but requires cardiac monitoring and may have other adverse effects that might not suit patients with multiple comorbidities; Option B (assumed to be Glatiramer Acetate) is the best choice due to its safety profile in patients with depression and autoimmune comorbidities; Options C and D are unspecified. 1) In RRMS patients with depression, avoid DMTs (such as interferon-beta) that may worsen mood. 2) Glatiramer acetate has a good safety profile in patients with multiple autoimmune conditions. 3) Always consider comorbidities when selecting a DMT. Recent guidelines and literature from neurology associations emphasize the individualized selection of DMTs based on efficacy, side effect profiles, and patient comorbidities. Glatiramer acetate remains a first\u2010line option particularly for patients with a history of mood disorders, supported by ongoing research and long-term safety data.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "image spinal MRI suggestive of demyelinating, the patient complaining of contractions & pain, the MRI is stable. What is the treatment:",
    "option_a": "Acetazolamide.",
    "option_b": "Carbamazepine.",
    "option_c": "Diazepam.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Patients with demyelinating spinal cord lesions, such as those seen in multiple sclerosis, may develop paroxysmal episodes of painful muscle contractions or spasms. These paroxysmal tonic spasms are a recognized phenomenon in demyelinating disorders and require symptomatic management. In demyelinated pathways, nerve fibers may become hyperexcitable due to altered ion channel distribution and impaired conduction. This abnormal excitability leads to paroxysmal discharges resulting in sudden, painful, and involuntary muscle contractions. Carbamazepine, an anticonvulsant, stabilizes hyperexcited neural membranes by inactivating voltage-gated sodium channels, reducing aberrant firing. The clinical scenario describes a patient with a stable spinal MRI (indicating no new active demyelinating lesions) who presents with painful contractions. These features are consistent with paroxysmal tonic spasms rather than an active inflammatory relapse, making symptomatic treatment with an anticonvulsant appropriate. Differential diagnoses include spasticity from active demyelination, muscle cramps (due to electrolyte imbalances), or other forms of neuropathic pain. The stability of the MRI helps to rule out an acute relapse. A thorough neurological exam combined with imaging and laboratory work helps differentiate these conditions. Carbamazepine is considered a first-line agent for treating paroxysmal tonic spasms in demyelinating diseases. Second-line options might include other anticonvulsants like lamotrigine. In pregnancy, carbamazepine is a known teratogen (risk of neural tube defects) so folic acid supplementation is mandatory and alternative therapies may be considered if the patient is planning pregnancy. During lactation, carbamazepine is excreted in breast milk, so monitoring the infant for side effects is advised. Option A (Acetazolamide) is generally not used for demyelination-related spasms, being more appropriate for conditions such as idiopathic intracranial hypertension. Option B (Carbamazepine) directly addresses the hyperexcitability causing paroxysmal spasms. Option C (Diazepam) might help relax muscles but is less specific for paroxysmal dyskinesias and carries risks of sedation and dependency. 1) Paroxysmal tonic spasms in MS can be effectively managed with carbamazepine. 2) Ensure folate supplementation when using carbamazepine in women of childbearing potential. 3) The stability of MRI findings can help distinguish symptomatic spasms from new inflammatory activity. Recent clinical studies and consensus guidelines support the use of carbamazepine for paroxysmal spasms in MS, with evidence showing improvement in pain and contraction frequency. Ongoing research is focusing on optimizing anticonvulsant dosing and exploring alternative agents with improved safety profiles in special populations.",
    "exam_year": "2019",
    "exam_type": "Promotion",
    "image_url": "page_6.png"
  },
  {
    "question": "young female with previous 2 optic neuritis attacks, came with new symptoms of spinal cord lesions. Aquaporin 4 is -ve, MRI showed C8-T10 lesions, what is the most likely Dx:",
    "option_a": "RRMS.",
    "option_b": "NMO",
    "option_c": "ADEM",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Neuromyelitis optica spectrum disorder (NMOSD), historically known as neuromyelitis optica (NMO), is a demyelinating condition that primarily affects the optic nerves and spinal cord. It is characterized by severe relapses of optic neuritis and transverse myelitis. NMOSD is typically mediated by autoantibodies against aquaporin-4 (AQP4). However, up to 30% of patients may be seronegative. Despite a negative AQP4 antibody test, the clinical and radiological features, such as longitudinally extensive transverse myelitis (typically affecting three or more vertebral segments, as seen here from C8 to T10) and recurrent optic neuritis, strongly indicate NMOSD. In some seronegative patients, myelin oligodendrocyte glycoprotein (MOG) antibodies may be implicated. A young female with a history of recurrent optic neuritis who now presents with a long segment spinal lesion is highly suggestive of NMOSD. In contrast, relapsing-remitting multiple sclerosis usually features shorter spinal cord lesions, and acute disseminated encephalomyelitis (ADEM) is typically a monophasic illness seen more often in children or post-infection. The diagnostic workup includes MRI of the brain and spinal cord, serologic testing for AQP4-IgG, and, when indicated, testing for MOG antibodies. Differential diagnoses include relapsing-remitting MS (characterized by shorter lesions and additional brain involvement) and ADEM (typically monophasic with encephalopathy). Acute attacks in NMOSD are managed with high-dose intravenous corticosteroids, often followed by a taper, and sometimes plasma exchange if corticosteroids are ineffective. Long-term immunosuppressive therapy (such as azathioprine, mycophenolate mofetil, or rituximab) is recommended for relapse prevention. Pregnancy considerations include weighing the benefits and risks of immunosuppressive therapy; for instance, azathioprine can be used during pregnancy with careful monitoring, while some agents like rituximab are generally avoided due to potential fetal risks. Option A (RRMS) is less likely because typical MS spinal cord lesions are shorter and have a different distribution; Option B (NMO) most closely fits the clinical scenario despite a negative AQP4 test, as NMOSD can be seronegative; Option C (ADEM) is generally a monophasic condition and does not account for a history of recurrent optic neuritis. 1) Longitudinally extensive transverse myelitis (\u22653 vertebral segments) is a hallmark of NMOSD. 2) A negative AQP4 antibody test does not exclude NMOSD if the clinical and radiographic picture is compelling. 3) Consider testing for MOG antibodies in seronegative cases with similar clinical features. Current research, including the 2015 international consensus diagnostic criteria for NMOSD, supports the diagnosis of NMOSD in cases with characteristic clinical presentations even in the absence of detectable AQP4 antibodies. Emerging data on MOG-associated disorders are refining our understanding of demyelinating diseases affecting the optic nerves and spinal cord.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "female patient with jaw claudication, temporal headache, she has joint pain & diffuse muscle ache, what is next?",
    "option_a": "ESR.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Giant cell arteritis (GCA) is a systemic vasculitis of medium and large arteries, most commonly affecting the temporal arteries. It often presents with a new-onset temporal headache, jaw claudication, and systemic symptoms such as muscle aches and joint pains. As GCA can lead to devastating complications like vision loss, prompt recognition and treatment are paramount. GCA is marked by a granulomatous inflammation of the arterial wall, leading to luminal narrowing and ischemia. The inflammatory process can compromise blood flow to the optic nerve, resulting in visual disturbances, and may also cause systemic symptoms due to cytokine release. A female patient presenting with jaw claudication and temporal headache, along with associated musculoskeletal discomfort, is highly suggestive of GCA. Jaw claudication is considered a red flag and a key diagnostic feature. The presence of systemic symptoms further supports an inflammatory vasculitis over other headache etiologies. Initial evaluation includes laboratory markers of inflammation such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Differential diagnoses include tension-type headache, migraines, and other systemic vasculitides. The definitive diagnosis is made with a temporal artery biopsy, although treatment should not be delayed if clinical suspicion is high. The immediate management of suspected GCA involves high-dose corticosteroids to prevent irreversible complications such as blindness. Although measurement of ESR is an important diagnostic step, the clinical scenario\u2014especially with jaw claudication\u2014often warrants prompt initiation of therapy. In pregnant or lactating women, corticosteroids remain the mainstay of treatment; however, the potential risks are generally outweighed by the risk of vision loss. Steroid-sparing agents may be considered in long-term management, but their use in pregnancy requires caution. Option A (ESR) is the appropriate initial laboratory test to evaluate for an inflammatory process in suspected GCA. The other options (B, C, and D) are not provided but would typically include advanced imaging or biopsy. Although immediate steroid treatment is critical in high-suspicion cases, checking ESR is a standard next step in the diagnostic workup. 1) Jaw claudication is a highly specific symptom for GCA and necessitates urgent evaluation. 2) Elevated ESR and CRP support the diagnosis, but treatment should not be delayed if clinical suspicion is very high. 3) Temporal artery biopsy remains the gold standard for diagnosis once the patient is stabilized. Recent guidelines emphasize rapid diagnosis and treatment of GCA to prevent irreversible vision loss. The American College of Rheumatology and other bodies recommend immediate corticosteroid therapy when clinical features highly suggest GCA, with inflammatory markers (ESR/CRP) used to support the diagnosis. Advances in imaging such as ultrasound may complement traditional biopsy in certain clinical settings.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "which of the following treatments cause rebound MS if stopped:",
    "option_a": "Fingolimod",
    "option_b": "Alemtuzumab",
    "option_c": "Ocrelizumab",
    "option_d": "Dimethyl fumarate",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question tests the awareness of rebound disease activity in multiple sclerosis when discontinuing a disease\u2010modifying therapy. Among available agents, fingolimod, a sphingosine\u20111\u2011phosphate receptor modulator, is known for causing rebound MS activity if stopped abruptly. Fingolimod works by sequestering lymphocytes in lymph nodes via functional antagonism of sphingosine\u20111\u2011phosphate receptors. When the drug is stopped suddenly, lymphocytes are released into the circulation, triggering an exaggerated inflammatory cascade in the central nervous system that can lead to new or worsening demyelinating lesions. Patients who discontinue fingolimod may present with new neurologic deficits or relapses that exceed their baseline disease activity. Magnetic resonance imaging (MRI) may show multiple active lesions. Clinically, this rebound phenomenon is serious and may require prompt management to prevent long\u2010term disability. The diagnosis is largely based on clinical history (recent stoppage of fingolimod) coupled with imaging that shows increased disease activity. Differential diagnoses include a spontaneous relapse of MS, infection-induced pseudo-relapse, or adverse effects from other medications. A detailed medication history is essential. Current guidelines recommend caution when discontinuing fingolimod. If discontinuation is necessary, a planned transition to another DMT is suggested. First-line strategy is careful tapering or overlap with another immunomodulatory agent. In cases of severe rebound, high-dose IV corticosteroids are used to control inflammation. In pregnancy and lactation, therapy choices should be individualized as MS patients require careful risk-benefit analysis and potential bridging strategies that are safe for both mother and fetus. Option A (Fingolimod) is correct because it is the treatment among those listed that is documented to cause rebound phenomena upon abrupt withdrawal. Alemtuzumab and Ocrelizumab are administered in infrequent dosing schedules and are not typically associated with a rebound upon discontinuation. Dimethyl fumarate has its own discontinuation concerns but is not as classically linked to rebound activity as fingolimod. 1. Always consider the risk of rebound when planning to discontinue fingolimod. 2. Overlap or transition strategies should be considered to minimize relapse risk. 3. Monitor patients closely after stopping fingolimod for any signs of renewed disease activity. Recent case series and reviews have reinforced that rebound MS activity is a significant risk with fingolimod cessation, leading to recommendations for careful planning when transitioning therapy. Ongoing research is evaluating optimal strategies for minimizing rebound effects during treatment switches.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Optic neuritis with pic what to give (painful visual loss in one eye with disc edema):",
    "option_a": "IV-methylpred",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Optic neuritis is an inflammatory demyelination of the optic nerve, frequently associated with multiple sclerosis. It typically presents with subacute, painful loss of vision and, in some cases, disc edema. The underlying mechanism involves autoimmune attack on the myelin of the optic nerve, leading to conduction block and inflammation. Cytokine release and blood\u2011brain barrier disruption further contribute to neural injury. Patients usually present with painful visual loss in one eye, often accompanied by dyschromatopsia and visual field defects. Fundoscopic exam may reveal optic disc edema, particularly in anterior optic neuritis. These clinical findings help differentiate it from conditions such as non-arteritic anterior ischemic optic neuropathy (NAION), which typically occurs in older patients and is painless. In addition to clinical evaluation, an MRI of the brain and orbit (with contrast) is the imaging modality of choice to assess for optic nerve enhancement. Differential diagnoses include NAION, compressive optic neuropathy, Leber\u2019s hereditary optic neuropathy, and neuromyelitis optica spectrum disorder (NMOSD). The first-line treatment for acute optic neuritis is high-dose intravenous methylprednisolone (IVMP) for 3\u20135 days, often followed by a tapering course of oral steroids. While IV steroids hasten visual recovery, they do not alter the ultimate visual outcome. In pregnancy and lactation, IV methylprednisolone therapy is generally considered safe if clearly indicated, though risk-benefit discussions and close monitoring are warranted. Option A (IV methylprednisolone) is correct because it is widely recognized as the treatment of choice for acute optic neuritis. The other options were not provided, but alternative therapies (such as oral steroids alone) are less preferred due to potential risk of recurrence. 1. Vision recovery is generally faster with IV steroid therapy even though final outcomes are similar. 2. Optic neuritis is often the first manifestation of MS; hence, careful follow-up is important. 3. Fundoscopic examination is key in differentiating optic neuritis from ischemic optic neuropathies. The Optic Neuritis Treatment Trial (ONTT) has been foundational in establishing the role of IV methylprednisolone in speeding the recovery of vision in optic neuritis. Ongoing studies continue to evaluate the long-term impact of steroids on disease progression in MS.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt w triad; areflexia, ophthalmoparysis, ataxia (miller fisher) what Rx?",
    "option_a": "IVIG or Plex",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Miller Fisher syndrome (MFS) is a rare, immune-mediated variant of Guillain-Barr\u00e9 syndrome characterized by a classic clinical triad: ophthalmoplegia, ataxia, and areflexia. MFS is thought to be caused by an autoimmune response, often post-infectious, with antibodies (notably anti-GQ1b) targeting peripheral nerves and cranial nerve fibers. This immunologic attack leads to demyelination and sometimes axonal damage, resulting in the characteristic neurological deficits. Patients with MFS present acutely with eye movement abnormalities (ophthalmoplegia), gait instability (ataxia), and diminished or absent deep tendon reflexes. In many cases, symptoms progress over days to weeks. It is important to differentiate MFS from other causes of ophthalmoplegia such as brainstem infarcts or myasthenia gravis. The diagnosis is primarily clinical. Cerebrospinal fluid (CSF) analysis may show albuminocytologic dissociation. Anti-GQ1b antibodies are commonly positive in Miller Fisher syndrome. Differential diagnoses include brainstem stroke, Bickerstaff brainstem encephalitis, and neuromuscular junction disorders. Both IV immunoglobulin (IVIG) and plasmapheresis (PLEX) are accepted first-line treatments in patients with Guillain-Barr\u00e9 syndrome variants, including MFS, especially in more severe cases or those with rapidly progressing symptoms. In many cases of MFS, the disease is self-limited, but treatment may hasten recovery. In pregnant and lactating patients, IVIG is highly favored because of its established safety profile compared to plasmapheresis, which may be more logistically challenging. Option A (IVIG or Plasmapheresis) is correct as both therapies have been used effectively to treat Miller Fisher syndrome. The other options were not provided, but the key point is that immune modulation via IVIG or PLEX forms the mainstream treatment for this condition. 1. Miller Fisher syndrome often has a good prognosis with timely treatment. 2. Anti-GQ1b antibody positivity is a supportive diagnostic marker. 3. Although many patients stabilize without treatment, IVIG can help shorten the duration of symptoms. Recent guidelines and studies confirm that IVIG is a safe and effective treatment for MFS. Studies comparing plasmapheresis and IVIG have generally shown similar efficacy with the advantage of easier administration and safety in pregnancy with IVIG.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "same scenario w different presentation dx?",
    "option_a": "PRESS",
    "option_b": "CVT",
    "option_c": "HSV",
    "option_d": "lupus cerebritis",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question evaluates the recognition of alternative neurovascular diagnoses in a patient with a clinical scenario that might be seen in a hypercoagulable state, particularly in young or peripartum women. Cerebral venous thrombosis (CVT) is a well\u2010recognized cause of stroke in the young and is especially associated with pregnancy and the postpartum period. In CVT, thrombosis occurs within the cerebral venous sinuses leading to impaired venous drainage. This causes an increase in intracranial pressure, venous congestion, and can result in venous infarctions or hemorrhage. Factors such as pregnancy or postpartum status, oral contraceptive use, and other hypercoagulable conditions elevate the risk. Clinically, CVT typically presents with an acute to subacute headache, sometimes accompanied by seizures, focal neurologic deficits, altered mental status, and signs of increased intracranial pressure. Differentiating CVT from disorders like Posterior Reversible Encephalopathy Syndrome (PRES), herpes simplex encephalitis, or lupus cerebritis depends on the clinical setting and imaging findings. The diagnostic work-up involves neuroimaging, with MRI combined with MR venography (MRV) or CT venography (CTV) being the gold standard for detecting venous sinus thrombosis. Differentials include: - PRES: usually seen with severe hypertension and characteristic posterior white matter edema. - HSV encephalitis: typically involves temporal lobe abnormalities and presents with fever and altered mental status. - Lupus cerebritis: seen in patients with known SLE, often with systemic signs. The cornerstone of CVT treatment is prompt anticoagulation. Low molecular weight heparin (LMWH) is recommended as first-line treatment, even in the presence of intracranial hemorrhage. After the acute phase, transitioning to oral anticoagulants is standard. In pregnant or lactating patients, LMWH is the agent of choice because of its safety profile compared to vitamin K antagonists. Second-line therapies (such as endovascular thrombolysis) are reserved for severe, refractory cases. Option A (PRES) is a hypertensive emergency, usually associated with preeclampsia/eclampsia and has a distinct radiologic pattern. Option B (CVT) is correct given the risk factors (especially in peripartum women) and clinical presentation. Option C (HSV encephalitis) generally presents with fever and temporal lobe involvement, which are not typical of the scenario described. Option D (lupus cerebritis) would require a history or laboratory evidence of systemic lupus erythematosus and typically features a broader spectrum of neuropsychiatric findings. 1. Always consider CVT in young women with headache and neurological deficits, especially in the peripartum period. 2. Early imaging (MRV/CTV) is key to a prompt diagnosis. 3. Anticoagulation is safe and effective even when small hemorrhagic infarcts are present. Recent guidelines emphasize early initiation of anticoagulation with LMWH for CVT, including in pregnant patients, with excellent outcomes when treated promptly. Ongoing research into endovascular therapies is expanding options for severe cases, but LMWH remains the standard of care.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Same as above scenario but came with !headache MRI pic Dx?",
    "option_a": "PRESS",
    "option_b": "RCVS",
    "option_c": "HSV",
    "option_d": "lupus cerebritis",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Headache is a common neurological symptom that can arise from a wide spectrum of etiologies, ranging from benign primary headache disorders to serious secondary causes involving vascular, infectious, or autoimmune processes. When headache is accompanied by MRI abnormalities, it mandates a careful evaluation of the underlying pathophysiology to distinguish among these etiologies. Understanding the neurovascular anatomy and the blood-brain barrier's role is essential, as many pathologies affecting cerebral vessels or parenchyma manifest with characteristic imaging patterns and clinical syndromes. For example, reversible cerebral vasoconstriction syndrome (RCVS) involves transient dysregulation of cerebral arterial tone, leading to segmental vasoconstriction and vasodilation, which can be detected on vascular imaging and correlated with clinical symptoms such as thunderclap headache. Comprehending the interplay between vascular tone, endothelial function, and inflammatory mechanisms allows a nuanced appreciation of how different disorders produce overlapping yet distinct clinical and radiographic findings. The MRI appearance of bilateral parieto-occipital vasogenic edema is characteristic of posterior reversible encephalopathy syndrome (PRES). Reversible cerebral vasoconstriction syndrome (RCVS) instead shows segmental arterial narrowing on angiography rather than the confluent white-matter edema seen in PRES. Patients with RCVS typically present with sudden-onset, severe thunderclap headaches often described as the worst headache of their life. The headaches can be recurrent over days to weeks. Neurological deficits may occur if ischemic strokes or hemorrhages develop. MRI may show ischemic lesions, and vascular imaging reveals segmental cerebral artery narrowing that reverses over weeks. PRES presents with headache, seizures, visual disturbances, and altered mental status; MRI shows symmetrical vasogenic edema in the parieto-occipital regions. HSV encephalitis manifests with fever, headache, altered consciousness, and focal neurological signs; MRI demonstrates asymmetric temporal lobe hyperintensities. Lupus cerebritis presents variably with headaches, cognitive dysfunction, seizures, or psychosis; MRI findings are nonspecific but may include white matter lesions or infarcts. Differentiating these based on clinical presentation and imaging is critical for appropriate management. Evaluation begins with detailed history and neurological examination, focusing on headache characteristics, onset, associated symptoms, and risk factors. MRI of the brain with and without contrast is essential to identify parenchymal lesions, edema, or hemorrhage. In suspected RCVS, vascular imaging via MR angiography, CT angiography, or digital subtraction angiography is critical to detect segmental arterial narrowing. Follow-up imaging after 1-3 months demonstrating resolution of vasoconstriction supports the diagnosis. CSF analysis helps exclude infectious or inflammatory causes; in RCVS, it is usually normal or shows mild nonspecific changes, whereas HSV encephalitis shows lymphocytic pleocytosis and elevated protein. Autoimmune panels and serologies aid in diagnosing lupus cerebritis. Diagnostic criteria for RCVS include thunderclap headache, reversible vasoconstriction on angiography, normal or near-normal CSF, and exclusion of other causes. According to the 2019 American Heart Association/American Stroke Association guidelines on RCVS, management focuses on symptomatic relief and removal of precipitating factors (e.g., vasoactive drugs). Calcium channel blockers such as nimodipine or verapamil are commonly used off-label to alleviate vasoconstriction, although evidence is primarily observational. Blood pressure should be carefully managed to avoid hypoperfusion. In contrast, PRES management targets blood pressure control and treating underlying causes like eclampsia or immunosuppressive withdrawal. HSV encephalitis requires urgent intravenous acyclovir. Lupus cerebritis treatment involves immunosuppression with corticosteroids and other disease-modifying agents. Prompt diagnosis and tailored therapy are crucial to prevent irreversible neurological damage. Option A (PRES): Although PRES can present with headache and MRI abnormalities, it typically shows vasogenic edema in the posterior white matter rather than the segmental vasoconstriction seen in RCVS. PRES is often associated with hypertension, eclampsia, or immunosuppressive therapy, which may not fit the clinical scenario.  Option B (RCVS): Correct. The clinical presentation of thunderclap headache combined with MRI findings of reversible segmental cerebral artery narrowing is characteristic of RCVS. It is distinguished by its reversible nature and lack of inflammatory CSF changes.  Option C (HSV encephalitis): Incorrect because HSV encephalitis usually presents with fever, altered mental status, and temporal lobe MRI abnormalities rather than isolated headache and vascular changes.  Option D (Lupus cerebritis): While lupus cerebritis can cause headache and MRI abnormalities, it usually occurs in the context of systemic lupus erythematosus with other systemic signs and shows more diffuse inflammatory changes rather than the focal vascular findings of RCVS. - Thunderclap headache is a hallmark of RCVS and should prompt vascular imaging. - RCVS can be triggered by vasoactive substances such as triptans, SSRIs, or illicit drugs. - PRES and RCVS can clinically overlap but differ in pathophysiology and imaging patterns. - Normal CSF helps distinguish RCVS from vasculitis or infectious causes. - Repeat vascular imaging is essential to confirm the reversibility of vasoconstriction. - Avoid corticosteroids in RCVS as they may worsen outcomes. - Memory aid: \"RCVS = Reversible Cerebral Vasoconstriction Syndrome = Thunderclap headaches + Reversible vasoconstriction.\" The 2019 American Heart Association/American Stroke Association scientific statement on RCVS states: \"Management of RCVS is largely supportive, with removal of precipitating factors and use of calcium channel blockers such as nimodipine or verapamil to relieve vasoconstriction. Although no randomized controlled trials exist, observational data support this approach.\" Knowledge gaps include the precise pathogenesis and optimal therapeutic strategies. Recent studies emphasize the importance of distinguishing RCVS from PACNS to avoid unnecessary immunosuppression. Advances in high-resolution vessel wall imaging may improve diagnostic specificity in the future. Ongoing research is needed to clarify the role of endothelial dysfunction and to develop targeted treatments.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt female admitted to psych ward she has delusion and hallucination then developed seizures and fever, dx?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "1",
    "subspecialty": "Neuroimmunology",
    "explanation": "Anti-NMDA receptor encephalitis is an autoimmune encephalitis that most commonly affects young females. It initially presents with psychiatric symptoms such as delusions and hallucinations and subsequently evolves to include neurological features such as seizures and fever. The association with ovarian teratomas further supports this diagnosis. This disorder is mediated by autoantibodies against the NR1 subunit of NMDA receptors in the brain, leading to receptor internalization and disrupted synaptic transmission. The immune response primarily affects the limbic system, producing psychiatric symptoms, and can also involve broader areas leading to seizures and autonomic instability. The patient\u2019s presentation\u2014a young female with a psychotic episode (hallucinations, delusions) that evolves into seizures and fever\u2014is characteristic of anti-NMDAR encephalitis. Such a clinical evolution is unusual in primary psychiatric disorders and helps distinguish this condition from other etiologies like infectious encephalitis or metabolic disturbances. Evaluation should include cerebrospinal fluid (CSF) studies to detect anti-NMDAR antibodies, which supports the diagnosis. Other investigations include brain MRI (which may sometimes show subtle or transient changes) and EEG (often demonstrating diffuse slowing). Pelvic imaging is also recommended to assess for ovarian teratomas. Differential diagnoses include herpes simplex virus (HSV) encephalitis (which often has focal neurological deficits and positive PCR findings), primary psychiatric disorders (which do not usually present with fever and seizures), and other autoimmune encephalitides (e.g., anti-LGI1 encephalitis, which has a different age and symptom profile). Management involves early initiation of immunotherapy, typically with high-dose corticosteroids, intravenous immunoglobulins (IVIG), or plasmapheresis. Surgical removal of an associated ovarian teratoma is essential when present. Antiepileptic drugs are used for seizure control. In pregnant or lactating patients, steroids and IVIG are generally considered safe, and a multidisciplinary approach is needed when considering surgical intervention or additional immunosuppressive therapies such as rituximab (while certain agents like cyclophosphamide are avoided during pregnancy). Alternative options such as infectious encephalitis (e.g., HSV) generally present with memory deficits and focal neurological signs, and primary psychiatric disorders do not typically feature fever or seizures. Anti-LGI1 encephalitis is more common in older adults and presents differently (e.g., faciobrachial dystonic seizures). Metabolic or toxic encephalopathies would not initially manifest with isolated psychiatric symptoms followed by seizures and fever as described here. Always consider anti-NMDAR encephalitis in young females who present with new onset psychiatric symptoms followed by seizures and fever. Early diagnosis is crucial and requires a high index of suspicion, particularly when evaluating patients in psychiatric settings. Screening for ovarian teratomas is an important part of the workup. Recent studies and clinical guidelines emphasize early immunomodulatory treatment to improve outcomes in anti-NMDAR encephalitis. Early tumor removal, if an underlying teratoma is identified, is also associated with better prognosis. In the context of pregnancy, current guidelines support the use of corticosteroids and IVIG due to their favorable risk profiles, while avoiding agents with teratogenic potential.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt w optic neuritis + MRI spine attached showed Long seq enhancement , ogb negative?, next? (I think 2 scenario about NMO)",
    "option_a": "Send for aquaporin4 (NMO)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The patient presents with optic neuritis along with longitudinally extensive spinal cord lesions on MRI and is negative for oligoclonal bands. This constellation of findings is highly suggestive of neuromyelitis optica spectrum disorder (NMOSD), a distinct autoimmune demyelinating condition that differs from multiple sclerosis (MS). Confirmatory testing for aquaporin-4 (AQP4) antibodies is critical in this setting. NMOSD is primarily mediated by IgG autoantibodies targeting aquaporin-4 water channels on astrocytes. This leads to complement activation, astrocytic damage, and subsequent demyelination. The pathology typically affects the optic nerves and spinal cord, causing severe attacks that can lead to significant neurological deficits. Patients with NMOSD frequently present with severe optic neuritis and transverse myelitis, often involving long segments of the spinal cord. The lack of oligoclonal bands in cerebrospinal fluid further distinguishes NMOSD from MS, where OCB positivity is common. The clinical scenario described fits the classic presentation of NMOSD. The diagnostic evaluation of suspected NMOSD involves neuroimaging and serologic testing. MRI findings of long segment spinal cord lesions combined with optic neuritis require differentiation from MS and idiopathic transverse myelitis. A negative OCB profile alongside the imaging findings heightens suspicion for NMOSD. The next appropriate step is to test for aquaporin-4 antibodies, which helps to confirm the diagnosis. Management of NMOSD focuses on both the acute attack and long-term relapse prevention. Acute management typically involves high-dose intravenous corticosteroids, with plasmapheresis considered for steroid-refractory cases. For long-term prevention, immunosuppressive therapies like rituximab, azathioprine, or mycophenolate are used. In pregnant or lactating patients, treatment selection must take into account fetal safety; corticosteroids are generally acceptable, while certain immunosuppressants may require adjustment or close monitoring during pregnancy and lactation per current guidelines. Option A, which directs the clinician to send for aquaporin-4 antibody testing, is the correct next step in the evaluation. Other unspecified options might delay the diagnosis or involve unnecessary workup. Confirming AQP4-IgG positivity is paramount in diagnosing NMOSD and in guiding subsequent therapy. A key clinical pearl is that the presence of optic neuritis combined with longitudinally extensive transverse myelitis and a negative OCB study should prompt evaluation for NMOSD. Early confirmation with AQP4-IgG testing is essential to start targeted immunosuppressive therapy and prevent further relapses, which is especially critical in populations such as women of childbearing age where treatment impacts pregnancy management. Recent studies and updated guidelines emphasize the necessity of early AQP4 antibody testing in cases suspicious for NMOSD. Evidence supports that prompt diagnosis and initiation of appropriate immunosuppressive therapy reduce relapse rates and long-term disability. This approach is endorsed by multiple neurology and immunology societies and is particularly relevant when managing special populations, including pregnant and lactating patients, where safety profiles of medications must be carefully considered.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Young male pt known case of RRMS ON natalizumab, he developed LL weakness and generalized numbness. Found to have in the labs Anti natalizumab Ab +ve. MRI: there are enhanced lesions. What is the treatment?",
    "option_a": "Plasma exchange",
    "option_b": "IVIG",
    "option_c": "prednisolone",
    "option_d": "is empty and thus not applicable.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question addresses the management of an acute relapse in a patient with relapsing\u2010remitting multiple sclerosis (RRMS) who is on natalizumab therapy. The key point is that the development of anti\u2010natalizumab antibodies can neutralize the drug, leading to breakthrough inflammatory activity as evidenced by contrast\u2010enhancing lesions on MRI and new neurological deficits. Natalizumab works by binding to the \u03b14-integrin on lymphocytes and blocking their migration across the blood-brain barrier, thereby reducing CNS inflammation. However, in some patients, the immune system develops neutralizing anti-natalizumab antibodies that eliminate the drug\u2019s efficacy. This loss of therapeutic effect precipitates renewed inflammatory demyelination, manifesting as clinical relapses and active lesions (seen as enhancement on MRI). The patient\u2019s presentation with lower limb weakness and generalized numbness, combined with MRI findings of enhancing lesions, is typical for an acute MS relapse. The additional finding of anti-natalizumab antibodies confirms that the relapse is mediated by immunogenicity against the therapy, leading to treatment failure. Diagnosis in this scenario involves correlating clinical relapse (new neurological symptoms) with radiographic evidence (contrast-enhancing lesions indicating active inflammation) and laboratory tests that reveal anti-natalizumab antibodies. Differential diagnoses would include other causes of CNS inflammation or demyelination (such as progressive multifocal leukoencephalopathy), though the imaging and clinical picture here favor an MS relapse due to treatment failure. The standard initial treatment for an MS relapse is high-dose intravenous corticosteroids. However, in cases where there is neutralization of natalizumab by antibodies\u2014especially if the clinical relapse is severe or refractory to steroids\u2014plasma exchange (PLEX) is indicated. PLEX helps remove the circulating anti-drug antibodies, reducing the immune-mediated stripping of natalizumab\u2019s effect and ameliorating the relapse. In pregnancy or lactation, high-dose steroids remain first-line, but plasma exchange may be pursued in steroid-refractory situations with careful maternal and fetal monitoring. Option A: Plasma exchange is correct because it directly removes the pathogenic anti-natalizumab antibodies, which is crucial in this scenario of antibody-mediated treatment failure and acute relapse. Option B: IVIG is not standard for an MS relapse in this context. Option C: Prednisolone (or high-dose IV corticosteroids) is typically used as a first-line agent for MS relapses but may be inadequate if the relapse is driven by significant neutralizing antibody effects. Option D is empty and thus not applicable. \u2022 The development of anti-natalizumab antibodies is a known phenomenon that can lead to breakthrough relapses in MS despite continued therapy.  \u2022 Plasma exchange is particularly useful in managing steroid-refractory relapses and in cases where antibody-mediated neutralization of therapy is suspected.  \u2022 In all MS relapse management scenarios, it is essential to assess the severity, and if standard therapy fails, escalate appropriately. Recent studies and guidelines from neurology societies support the use of plasma exchange in severe or steroid-refractory MS relapses, particularly in the context of neutralizing anti-drug antibodies. This approach is supported by evidence showing improved outcomes when pathogenic antibodies are removed, allowing for better control of the inflammatory process.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "same scenario above asking for management",
    "option_a": "steroid ....",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Acute inflammatory neurological events \u2013 such as relapses in multiple sclerosis or other demyelinating conditions \u2013 are managed by promptly reducing the immune-mediated inflammation. High\u2011dose corticosteroids are widely recognized as first\u2011line therapy due to their potent anti\u2010inflammatory and immunomodulatory effects. In disorders like MS or acute disseminated encephalomyelitis, immune cells attack myelin sheaths causing conduction block and neurologic deficits. Corticosteroids decrease cytokine production, stabilize the blood\u2011brain barrier, and limit further immune cell infiltration, thereby reducing edema and hastening recovery. Patients typically present with sudden onset of neurological deficits (e.g., sensory disturbances, motor weakness). The rapid improvement seen with steroid administration underscores its effectiveness in mitigating inflammatory damage during the acute phase. Diagnosis of an acute inflammatory event is primarily clinical and supported by MRI findings (e.g., enhancing lesions in MS). Differential diagnoses include stroke, infection, or metabolic abnormalities. Confirmatory tests (such as CSF studies or further serologic workup) may be used to rule out mimickers as needed. First\u2011line treatment is high\u2011dose intravenous corticosteroids (e.g., methylprednisolone 1 g daily for 3\u20135 days). In pregnant women, steroids are generally acceptable with careful monitoring, as high\u2011dose therapy is usually transient. For lactating patients, corticosteroids are considered relatively safe with minimal transfer to breast milk, though timing of feeds may be adjusted. Second\u2011line therapies (such as plasmapheresis or IVIG) are reserved for steroid\u2011refractory cases. Option A (steroids) is correct because it directly addresses the inflammatory process. Alternative options might include therapies targeting alternative mechanisms (e.g., anticoagulation or antiviral therapy) but would not be appropriate in an inflammatory demyelinating context. 1. Early administration of high\u2011dose steroids can shorten the duration of an acute relapse. 2. MRI confirmation is crucial for supporting a clinical diagnosis. 3. Pregnancy and lactation require careful steroid management but generally do not preclude use. Recent guidelines from neurology societies (such as the American Academy of Neurology) continue to support high\u2011dose IV corticosteroids as the standard for managing acute neuroinflammatory events. Ongoing studies are further refining dosing and duration strategies to optimize long\u2011term outcomes.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Scenario of MS pt asked about dx? (I did not remember the scenario try to review Mcdonald criteria)\n1-Time and space criteria were applied\n2-CIS",
    "option_a": "Time and space criteria were applied",
    "option_b": "CIS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is diagnosed based on evidence that lesions have occurred in different regions of the central nervous system (dissemination in space) and at different times (dissemination in time). This is the hallmark of the McDonald criteria. MS involves an autoimmune-mediated attack on myelin with resultant focal lesions that appear sporadically. The temporal and spatial development of these lesions underpins both clinical symptoms and imaging findings. Patients may present with varied neurological deficits separated by time. Although the first episode is often labeled as a clinically isolated syndrome (CIS), definitive MS diagnosis requires proof of dissemination in time and space through serial clinical assessments or MRI evidence. The diagnostic workup includes MRI studies which reveal lesions in different CNS areas and possibly the presence of oligoclonal bands in CSF. Differential diagnoses include neuromyelitis optica, acute disseminated encephalomyelitis, and vascular causes, but these are differentiated by imaging patterns and ancillary testing. An accurate diagnosis is key to initiating disease\u2011modifying therapies (DMTs) early. First\u2011line DMTs include interferon\u2011beta, glatiramer acetate, and newer oral agents. In pregnancy, many DMTs are contraindicated, so treatment strategies may shift to safer options or deferred initiation, with careful lactation counseling. Option A (Time and space criteria were applied) is correct as the McDonald criteria inherently require dissemination in both time and space to label the condition as MS. Option B (CIS) describes the initial episode but does not fulfill the criteria for a definite MS diagnosis. 1. The McDonald criteria streamline MS diagnosis by focusing on dissemination in time and space. 2. A diagnosis built solely on a CIS is premature without additional supportive evidence. 3. Early initiation of DMTs can alter long\u2011term prognosis. Recent updates to the McDonald criteria have allowed for more rapid diagnosis of MS using advanced MRI techniques, and current studies continue to refine these criteria to allow earlier intervention with DMTs.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Young lady with 2 miscarriages and has livedo reticularis, what to order:",
    "option_a": "Anti-phospholipid",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies, leading to thrombosis and obstetric complications such as recurrent miscarriages. In APS, antibodies (including lupus anticoagulant, anticardiolipin, and anti-beta2 glycoprotein I) interact with phospholipid-binding proteins, promoting a hypercoagulable state. This results in microthrombi that can impair placental blood flow and cause skin manifestations like livedo reticularis. The presentation of recurrent miscarriages along with livedo reticularis is highly suggestive of APS. Such patients are at risk for both arterial and venous thromboses and often require prompt evaluation and management to prevent further complications. The workup for APS includes ordering an antiphospholipid antibody panel (testing for lupus anticoagulant, anticardiolipin antibodies, and anti-beta2 glycoprotein I). Differential diagnoses include inherited thrombophilias and other autoimmune conditions (e.g., SLE), but the constellation of recurrent miscarriage and livedo reticularis points strongly to APS. First\u2011line management involves antithrombotic therapy \u2013 during pregnancy, low\u2011dose aspirin combined with prophylactic heparin has been shown to reduce miscarriage rates. Outside of pregnancy, long-term anticoagulation (usually with warfarin) is standard. For pregnant patients, low molecular weight heparin is preferred, and for lactating women, these agents are generally safe with minimal passage into breast milk. Option A (Anti\u2011phospholipid) is correct because it directly targets the diagnostic workup for APS. Other potential tests might not specifically confirm the hypercoagulable state tied to recurrent pregnancy loss and livedo reticularis. 1. Recurrent miscarriages in a young woman should raise suspicion for APS, especially when accompanied by skin changes like livedo reticularis. 2. A comprehensive antiphospholipid antibody panel is essential for diagnosis. 3. Combined antiplatelet and anticoagulant therapy during pregnancy improves outcomes in APS. Current guidelines from rheumatology authorities (e.g., the American College of Rheumatology) and updated Sydney criteria reiterate the importance of early APS diagnosis. Studies continue to support the use of aspirin and heparin in reducing pregnancy-related complications in APS.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Case scenario about pt have recurrent oral ulcer, present with neurological deficit: I think 2 scenario about neuro behcet",
    "option_a": "Neuro behcet",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Behcet's disease is a systemic vasculitis that primarily involves mucocutaneous lesions (notably recurrent oral and genital ulcers) and can also affect the eyes, skin, and central nervous system. When the CNS is involved, it is referred to as neuro\u2011Behcet\u2019s disease. The exact pathogenesis of Behcet's remains unclear, but it is believed to involve an aberrant immune response to environmental triggers in genetically predisposed individuals (notably those with HLA\u2011B51). Inflammation of blood vessels (vasculitis) can lead to a range of neurological manifestations when the CNS is affected. Patients with Behcet's typically present with recurrent oral aphthous ulcers, which are often accompanied by genital ulcers, uveitis, and skin lesions. When neurological deficits occur, they can manifest as meningoencephalitis, intracranial hypertension, or focal neurological deficits. This clinical picture is highly characteristic of neuro\u2011Behcet\u2019s. Diagnosis is primarily clinical, based on established criteria (such as the International Study Group criteria for Behcet's). Differential diagnoses include multiple sclerosis, systemic lupus erythematosus, and sarcoidosis. However, the recurrent nature of oral/genital ulcers combined with neurological symptoms strongly supports neuro\u2011Behcet\u2019s. Initial treatment typically involves high\u2011dose corticosteroids to control inflammation. Immunosuppressants such as azathioprine or cyclophosphamide are often used for maintenance, especially in severe cases. Biologic agents like TNF\u2011alpha inhibitors are emerging as options in refractory cases. In pregnant patients, corticosteroids are generally the safest option, while many immunosuppressants require careful risk\u2013benefit analysis. In lactation, medication selection is similarly cautious, as some agents can pass into breast milk. Option A (Neuro\u2011Behcet) is correct because the combination of recurrent oral ulcers and neurological deficits is a classic presentation of neuro\u2011Behcet\u2019s disease. Alternatives would not account for the multisystem inflammatory nature of the condition. 1. Recurrent aphthous ulcers with neurological symptoms should prompt evaluation for Behcet\u2019s disease. 2. Neuro involvement in Behcet\u2019s requires aggressive immunosuppressive therapy to prevent permanent damage. 3. Early identification and treatment can significantly alter the disease course. Recent research increasingly supports the use of biologic agents (such as TNF\u2011alpha inhibitors) in patients with refractory neuro\u2011Behcet\u2019s. Updated guidelines stress early intervention with steroids and immunosuppressants to prevent irreversible neurological damage.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "young Pt with hx of encephalopathy, weakness and hearing loss MRI brain showed ?",
    "option_a": "susac",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Susac syndrome is a rare autoimmune microangiopathy that affects the small vessels of the brain, retina, and cochlea. It classically presents with a clinical triad involving encephalopathy, sensorineural hearing loss, and branch retinal artery occlusions. The underlying mechanism involves an immune-mediated endotheliopathy that leads to occlusion of precapillary arterioles. This results in microinfarctions in the corpus callosum (typically seen as central 'snowball lesions' on MRI), retina, and cochlea. Recent studies indicate that an inflammatory process, perhaps triggered by viral or other environmental factors in genetically predisposed individuals, plays a key role. Patients, often young women, present with varied neurological symptoms (encephalopathy or confusion), focal deficits such as weakness, and sensorineural hearing loss. Visual symptoms may also occur due to retinal ischemia. The MRI findings along with the clinical triad are highly suggestive of Susac syndrome. Diagnosis relies on a combination of clinical features, MRI brain (showing characteristic lesions especially in the corpus callosum), fluorescein retinal angiography, and audiometry. Differential diagnoses include multiple sclerosis, acute disseminated encephalomyelitis (ADEM), and other small vessel vasculitides. Careful evaluation of the clinical triad helps differentiate Susac syndrome from these conditions. Management typically involves aggressive immunosuppression. First-line treatment includes high-dose corticosteroids (e.g., IV methylprednisolone) and intravenous immunoglobulin (IVIG). Second-line or adjunct therapies can include cyclophosphamide or mycophenolate mofetil. For patients who are pregnant or lactating, corticosteroids and IVIG remain relatively safe and are preferred over agents with known teratogenic potential. Option A (Susac) is correct because the patient\u2019s presentation of encephalopathy, weakness, and hearing loss is characteristic of Susac syndrome. The other options are not provided, but none would explain the unique triad as effectively. 1. Remember the classic triad: encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. 2. The central 'snowball' lesions in the corpus callosum are key MRI findings. 3. Early recognition and treatment with immunosuppressants can prevent irreversible damage. Current research supports early aggressive immunotherapy to limit permanent neurological deficits. Advances in MRI techniques continue to refine the diagnostic criteria, and updates in immunomodulatory therapies are being assessed for better long-term outcomes.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Long case with features of encephalitis and ovarian tumor:",
    "option_a": "Anti NMDA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Anti-NMDA receptor encephalitis is a type of autoimmune encephalitis most commonly associated with ovarian teratomas, particularly in young women. It involves the production of antibodies against the NR1 subunit of NMDA receptors in the brain. The presence of neural tissue within ovarian teratomas may trigger an autoimmune response. Antibodies produced against NMDA receptors cross-react with brain tissue, leading to receptor internalization and a resultant decrease in synaptic NMDA receptor density, which disrupts neurotransmission. Clinically, patients often present with a mix of psychiatric symptoms, memory deficits, seizures, and movement disorders. The association with ovarian tumors (typically teratomas) is a key feature, prompting oncological evaluation along with neurological workup. Diagnosis is confirmed by detecting anti-NMDA receptor antibodies in the cerebrospinal fluid (CSF) and serum. Neuroimaging (which may be normal or show nonspecific changes) and ovarian imaging (ultrasound or MRI) to identify teratomas are important. Differential diagnoses include viral encephalitis and other autoimmune encephalitides (e.g., LGI1 antibody encephalitis), but the demographic and association with ovarian mass are distinguishing. Management involves prompt tumor removal if present and immunotherapy. First-line treatment options include high-dose corticosteroids, IVIG, and plasma exchange. In refractory cases, second-line therapies such as rituximab or cyclophosphamide may be used. In pregnant or lactating patients, tumor resection is critical and immunotherapies, particularly corticosteroids and IVIG, are preferred because of their safety profiles compared to other agents. Option A (Anti NMDA) is the correct answer as the presentation of encephalitis in the context of an ovarian tumor is classic for anti-NMDA receptor encephalitis. Alternative options would not typically be associated with ovarian tumors, making them less likely. 1. Always consider anti-NMDA receptor encephalitis in young women with psychiatric symptoms, seizures, and abnormal movements. 2. The link between ovarian teratoma and encephalitis should prompt early tumor screening. 3. Early immunotherapy significantly improves outcomes. Recent guidelines emphasize early tumor resection combined with immunotherapy for improved neurological recovery. Ongoing research focuses on optimal immunosuppressive strategies and long-term outcomes, with favorable responses when treatment is initiated promptly.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Young lady with SLE who has a neurological deficit?. What is your diagnosis?",
    "option_a": "(Intracerebral hemorrhage) is less likely given the clinical context and the typical presentation in young SLE patients. Option B (Cerebral venous thrombosis) is correct due to its known association with SLE",
    "option_b": "",
    "option_c": "(PRES) is less likely because it typically presents with a broader encephalopathic picture and visual disturbances. Option D (Lupus cerebritis) generally causes diffuse neuropsychiatric symptoms rather than isolated focal deficits.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuroimmunology",
    "explanation": "In patients with systemic lupus erythematosus (SLE), neurological deficits can arise from various complications. Cerebral venous thrombosis (CVT) is a recognized neurovascular complication in SLE, particularly in the presence of antiphospholipid antibodies. SLE predisposes patients to both vasculitis and a hypercoagulable state, particularly when accompanied by antiphospholipid syndrome. CVT occurs when thrombi form in the dural venous sinuses, leading to impaired drainage, venous congestion, and potentially venous infarction or hemorrhage. Clinically, CVT can present with headache, seizures, and focal neurological deficits related to venous infarctions. Although intracerebral hemorrhage and other complications can occur, the focal deficits and subacute onset make CVT a strong consideration in a young SLE patient. The gold standard for diagnosis is MRI combined with MR venography. Differential diagnoses include intracerebral hemorrhage (which typically presents with sudden deficits and is less common in young SLE patients), PRES (posterior reversible encephalopathy syndrome, which usually presents with encephalopathy and visual disturbances), and lupus cerebritis (which more often causes diffuse neuropsychiatric symptoms). The first-line treatment for CVT is anticoagulation, typically with low molecular weight heparin (LMWH) followed by oral anticoagulants. In cases where there is significant hemorrhage, careful risk-benefit analysis is needed. In pregnant patients, LMWH remains the treatment of choice due to its safety profile. Management may also include treating underlying SLE with immunomodulatory agents as indicated. Option A (Intracerebral hemorrhage) is less likely given the clinical context and the typical presentation in young SLE patients. Option B (Cerebral venous thrombosis) is correct due to its known association with SLE-related hypercoagulability. Option C (PRES) is less likely because it typically presents with a broader encephalopathic picture and visual disturbances. Option D (Lupus cerebritis) generally causes diffuse neuropsychiatric symptoms rather than isolated focal deficits. 1. Always consider a hypercoagulable state in SLE patients, especially those with antiphospholipid antibodies. 2. MR venography is essential for diagnosing CVT. 3. Anticoagulation remains the cornerstone of therapy even in the presence of small hemorrhages. Recent clinical guidelines advocate for early recognition and anticoagulation management of CVT in SLE patients, with special attention given to patients with antiphospholipid syndrome. There is also ongoing research into the optimal duration of anticoagulation in these patients.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Young lady with SLE, seizures and vitals: temp 39 with image of temporal lobe involvment:",
    "option_a": "HSV enphalitis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Herpes simplex virus (HSV) encephalitis is the most common form of sporadic encephalitis. It characteristically involves the temporal lobes and presents with fever, seizures, and focal neurological deficits. HSV-1 typically invades the brain via retrograde neuronal transmission, leading to necrotizing encephalitis. The temporal lobes are preferentially involved, which explains the clinical and imaging findings. Although patients with SLE are at risk for various neurological complications, the presence of fever, seizures and focal temporal lobe involvement strongly suggests an infectious etiology rather than a purely autoimmune process. The clinical presentation of high fever, seizures, and changes in mental status, combined with MRI findings of temporal lobe abnormalities, are highly suggestive of HSV encephalitis. In SLE patients, while neuropsychiatric lupus (lupus cerebritis) is a concern, the acute presentation with fever and temporal lobe involvement is more typical for an infectious process. The diagnosis is confirmed with a lumbar puncture to obtain CSF for HSV PCR, which is highly sensitive and specific. Differential diagnoses include lupus cerebritis (which usually presents with more diffuse or psychiatric symptoms) and other forms of encephalitis. MRI findings showing hyperintensities in the temporal lobes further support the diagnosis of HSV encephalitis. Immediate initiation of intravenous acyclovir is the standard of care and is a medical emergency, as delayed treatment can lead to significant morbidity or mortality. In pregnant or lactating patients, acyclovir is considered safe and is the treatment of choice. The recommended regimen is typically 10 mg/kg IV every 8 hours for 14\u201321 days, with dose adjustments as needed for renal function. Option A (HSV encephalitis) is correct because the combination of fever, seizures, and temporal lobe involvement on MRI most strongly indicates HSV encephalitis. Other options such as lupus cerebritis are less likely given the focal imaging findings and systemic signs of infection (fever). 1. Temporal lobe involvement on MRI is a red flag for HSV encephalitis. 2. Early empirical treatment with acyclovir is crucial even before confirmatory PCR results are available. 3. HSV encephalitis remains a neurologic emergency requiring prompt intervention. Recent studies continue to show that early initiation of acyclovir drastically improves outcomes. Guidelines stress the importance of early lumbar puncture and PCR testing for HSV in suspected encephalitis cases. In SLE patients, clinicians must differentiate infectious from autoimmune causes to ensure appropriate management.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  }
]